Divis Laboratories tumbled 9.58% to Rs 2,954.10 after the pharmaceutical company's consolidated net profit slumped 66% to Rs 306.80 crore on 31.51% decline in revenue from operations to Rs 1,707.68 crore in Q3 FY23 over Q3 FY22.
Total income stood at Rs 1,821.93 crore in Q3 FY23, down 27.41% from Rs 2,509.86 crore recorded in the same period a year ago. Material consumption for this quarter came to be about 43% of sales revenue due to change in product mix.
Consolidated profit before tax dropped 57.86% to Rs 435.63 crore in the quarter ended 31 December 2022 as compared to Rs 1,033.66 crore posted in Q3 FY22.
Total expense decreased by 6.09% year on year to Rs 1,386.30 crore in Q3 FY23. Cost of material consumed was at Rs 604.40 crore (down 32.93% YoY) and employee benefit expenses stood at Rs 238.88 crore (down 2.35% YoY) during the period under review.
On a standalone basis, the company net profit tumbled 65.73% to Rs 310.90 crore on 31.5% fall in revenue to Rs 1,689.83 crore in Q3 FY23 over Q3 FY22.
Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients.
Powered by Capital Market - Live News